HK2 and hepatocellular carcinoma: Furthermore, the invasive and metastatic activities of HCC cells were significantly reduced following treatment with the HK2 inhibitor 2‐DG (Figure S4E,F, Supporting Information), which contrasts with the increased invasive and metastatic activities observed in RNASET2KO HCC cells.